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1196-17 The Impact of Intracoronary Redlatlon on In-Stent 
Reetenosis Involving Ostlal Lesions 
Andrew E. Aiani. Edouard Cheneau, R. Larry White, Hongsheng Wu, Harold Yazdi, 
George Aggrey, Dancia Langley, Ellen Pinnow, Augusto D. Pichard, Lowell F. Satler, 
Kenneth M. Kent, Joseph Lindsay, Ron Waksman, Washington Hospital Center, 
Washington, Dist. of Columbia. 
Background: Coronary interventions in ostial lesions have a high rate of recurrence of 
restenosis. The aim of this study was to compare 6-month clinical and angiographic out- 
comes of patients (pts) with in-stent restenosls (ISR) involving the ostium treated with 
intra-coronary radiation therapy (IRT) compared to placebo and also to non-ostial esions 
treated with IRT. Methods: We assessed 1295 pts enrolled in gamma (192-Iridium) and 
beta (90-Yttrium) radiation tdals for ISR at the Washington Hospital Center. Of pts receiv- 
ing IRT, 99 (6%) pts had ostial ISR and 1169 (90%) pta had non-ostler ISR, and only 27 
pts had ostial ISR and were treated with placebo. Results: Baseline demographic, 
anglegraphic and procedural details were similar, except ostial IRT pts had a trend 
towards shorter lesions (14.0~10.6 vs. 32.4+14.3 ram, p=0.06), and had a higher rate of 
saphenous vein graft disease (47% vs. 19%, p<0.001), compared to non-ostial IRT pts. 
Ostial lesions treated with IRT for ISR had a reduced rate of recurrent restenosis com- 
pared to ostial lesions treated with placebo (Table). Outcomes at 6 months including res- 
tenosis rates were similar for the ostlel and non-ostlel IRT group. Conclusions: 
Intracoronary radiation continues to be effective for ostial in-stant restenotic lesions and 
should be comfortably used for this challenging anatomic location. 
Clinical and Anglographic Outcomes at 6 Months 
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IRT Placebo 
Ostial (N=99) Non-Ostial (N=1169) Ostial (N=27) 
Angiographic Restenosis, % 11 29* 551" 
Late Loss, mm 0.33i-O.70 0 .47 i~) .72  0.99-Z0.641. 
TVR, % 23 22 501" 
MACE, % 25 22 541- 
Late Total Occlusion, % 2 4 4 
*P < 0.05 IRT Ostial vs. IRT Non-Ostial, 
1.P < 0.05 IRT Ostial vs. Placebo Ostial 
1196-18 High Dose Intrecoronary Gamma Radiation for Patients 
With Diffuse In-Stent Reetenoais: Six Versus One Month 
of Antlplatelet Therapy 
non Waksman, Andrew E. Ajani, Edouard Cheneau, Dong-Hun Cha, Hongsheng Wu, 
Chad Brown, Michael Porrazzo, Lowell F. Satler, Augusta D. Pichard, Kenneth M Kent, 
Ellen Pinnow, Joseph Lindsay, Washington Hospital Center, Washington, Dist. of 
Co/urnbia. 
Background: The Washington Radiation for In-Stent Restenosis Trial for long lesions, 
utilizing high dose (18 Gy) of intracoronary radiation therapy linT): LONG WRIST HIGH 
DOSE, aimed to determine the safety and efficacy of higher doses of 3' IRT for the treat- 
ment of patients (pts) with diffuse in-stent restenosis (ISR). Methode: One hundred and 
twenty pts with diffuse ISR in native coronary arteries (lesion length 36-80 mm) under- 
went PTCA, atherectomy, and/or additional stants. The prescribed dose was 18 Gy at 2.0 
mm, with a mean ribbon length of 69 ± 6 mm. Six month (mo) clinical outcomes of 60 pts 
treated with 1 mo of Clopidogrel were compared to 60 pts with 6 mos of Clopidogrel. 
Additional comparison was made to pts from LONG WRIST who were randomized to pla- 
cebo (n=61) or 192-1r with a prescribed dose of 15 Gy at 2 mm (n=60) with 1 mo of Ticlo- 
pidine. Results: All 120 pts treated with 18 Gy underwent successful InT. The overall 
events at 6 mos were lower in the high dose group compared to pts treated with 15 Gy or 
placebo (Table). Six mos of antipletelet therapy (APT) in the high dose group was associ- 
ated with less thrombotic events when compared to one mo of APT. Conclusions: High 
dose radiation (18 Gy) using t92-1r for diffuse ISR is safe and effective (compared to 
control and a dose of 15 Gy). Prolonged antiplatalet herapy continues to be protective 
for late thrombosis even in higher doses of radiation. 
18Gy 1M 18Gy 6M 15Gy 1M Placebo 1M P 
APT(N=60) APT(N=60) APT(N--60) APT(N=61) 
Death, % 0 0 5 2 0.11 
Q-Wave MI, % 0 5 5 0 0.10 
TLR, % 18 14 30 57 <0.001 
TVR, % 28 17 33 57 <0.001 
MACE, % 28 16 37 59 <0.001 
Late Thrombosis, % 8 2 10 5 0.20 
1196-19 Prolonged Antlplatelet Therapy and Reduced Stenting 
Eliminates Late Thrombos is  After Radiation: The 
Scripps III Trial 
Paul S. Teiratain, Jeffrey W. Moses, Martin B. Leon, Peter J. Cestarelle, John P. Reilly, 
Huan Giap, Shirish Jani, Steven Baiter, Prebhakar Tdpuraneni, Alexandra Lansky, 
Manuela Negoita, Roxanna Mehran, Scripps Clinic, La Jol/a, California, Lenox Hill 
Hospital, New York, New York. 
Background: While the efficacy of coronary brachytherapy for the treatment of in-stent 
restenosis has been well established, recent reports of excess late thrombosis, leading 
to myocardial infarction, have raised safety concerns. Previous studies have linked 
thrombotic episodes to new stent implantation and earty discontinuation of antiplatelet 
therapy. The objective of the SCRIPPS III study was to evaluate the impact of both 
reduced additional stent implantation and enhanced adjunctive antiplatalet herapy on 
late target thombosis following brachytherapy. 
Methods: At two centers (Scripps Clinic and Lenox Hill) vigorous attempts were made to 
avoid implanting new stants prior to treatment of in-stent restenosis with gamma radia- 
tion. Patients who did not receive new stants were discharged on clopidogrel (75rag per 
day after a 300mg loading dose) for 6 months and patients who received new stants 
were treated with clopidogrel for 12 months. All patients received aspirin, 325mg, indefi- 
nitely. 
Results: Enrollment in this 500 patient registry was completed on 9/12/00; 33.8% had 
diabetes, 15.2% had treatment of a saphenous vein graft and 39% were treated with a 
radiation source wire >_ 55mm in length. New stants were implanted in only 22.7% of 
study patients. The mean current follow-up time is 11.1 months. Clopidogrel has been 
discontinued for more than 1 month in 243 (48.6%)patients. To date, one patient who 
received a new stant sustained an acute stant thrombosis ix hours after the index radia- 
tion procedure due to distal dissection and two patients who received a new stant sus- 
tained a stant thrombosis within two weeks following radiation. There have been no late 
(_> 30 day) thromboses. 
Conclusion: Minimizing new stant implantation and treatment with prolonged adjunctive 
antiplatelet herapy appears to eliminate late target thrombosis after coronary brachy- 
therapy. Final follow-up results will be presented. 
1196-20 Interprocedural Interval as a Risk Factor for Recurrent 
Restenosis After Treatment of In-Stent Reetenosis: 
Differential Response With and Without Brechytherapy 
Michael P. Savaoe, David L. Fischman, Richard K. Valicenti, Warren K. Laskey, 
Theodore A. Bass, Paul S. Teirstein, Jeffrey J. Popma, Richard Kuntz, START 
Investigators, Jefferson Medical College, Philadelphia, Pennsylvania. 
In patients undergoing reintervention for in-stant restenosis, a short interval (<90 days) 
between index and repeat procedures has been identified as an important risk factor 
associated with recurrent restenosis. We hypothesized that brachytherapy (due to its 
effects on actively dividing cells) would have greater benefit in patients with short inter- 
procadural intervals and would minimize the importance of the temporal interval as a pre- 
dictive factor for restenosis. In this START substudy, the effect of beta-radiation vs 
placebo for the treatment of in-stent restenosis was assessed as a function of the interval 
between procedures. Compared to patients with intervals >90 d, patients with early rest- 
enosis (<90 d) had smaller vessels (2.66 vs 2.83 mm, p<.05) and were more likely to 
have class Ill/IV angina (71 vs 50%, p=.01). Multivariabte modeling for recurrent in-stent 
restenosis demonstrated a significant interaction between the interprocedural interval 
and restenosis; patients with a prior procedure <90 d had higher restenosis dsk (odds 
ratio 5.58, p=.O01). Multivariable modeling also demonstrated a significant benefit asso- 
ciated with Sr90 therapy (odds ratio 0.42, p<.05). An interaction between assigned ther- 
apy and interprocedurai interval was observed. The relation between the interval and 
restenosis was different for Sr90 vs placebo in that radiation markedly reduced the time 
effect. For Sr90 patients, recurrent restenosis was comparably low in both early and late 
groups (11.8 vs 13.6%). In contrast, placebo patients with early repeat procedures were 
at higher risk of restenosis (66.7 vs 26.4%). Thus, the relative treatment effect of radia- 
tion was greater in the early procedure group than in the late group (82 vs 48% reduc- 
tion). 
Conoluelone: (1) Risk of in-stent restenosis is inversely related to the interprocadural 
interval - patients with restenosis within 90 days have higher risk of recurrent restenosis; 
(2) The relative effect of b-radiation is greater in patients undergoing eady repeat proce- 
dures but the absolute restenosis rates are low irrespective of the interprocadurel inter- 
val; (3) Brachytherapy eliminates the effect of the temporal interval on recurrent 
restenosis. 
1196-21 Retreatment Immediately After Gamma Radiation for  In- 
Stant Reetenosia Results in Need for  Target Vessel 
RevaecularizaUon Beyond Target Lesion 
Makoto Hirese. Yoshio Kobayashi, Roxana Mehran, Issam Moussa, George Dangas, 
Ramona Pop, Milena Adamian, Michael Collins, Mark A. Gdse, Alexandra J. Lansky, 
Gary S. Mintz, Gregg W. Stone, Jeffrey W. Moses, Martin B. Leon, Paul S. Teirstein, 
Cardiovascular Research Foundation, New York, New York, Scripps Clinic, San Diego, 
California. 
Background: Repeat balloon angioplesty or stenting (re-traatment) immediately after 
gamma radiation for in-stent restenosis (ISR) is sometimes required, usually due to acute 
recoil. However, little is known about short and Iong-tarm outcomes after re-treatment fol- 
lowing brachytherapy. 
Methods: Balloon angioplasty plus gamma radiation was pedormed in 154 ISR lesions. 
Re-treatment after brachytherapy was required in 48 lesions (31%). 
Results: Baseline clinical characteristics were similar between the 2 groups. There were 
no late thromboses. In the subset of lesions with no new stents, TVR (target vessel 
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reveecuiadzetion) without TLR (target lesion reveecuiarization) was higher in those with 
re-trsatment compared to no re-treatment (19.2% vs. 3.4%, p--0.02). 
Conclusions: Re-treatment after gamma radiation Is performed in one-third cases, often 
resulting in additional stent implantation. Re-treatment is associated with increased TVR 
at follow-up, probably due to injury outside the irradiated segment. If re-treatment is 
required, vigorous efforts to avoid injury to inadequately irradiated vessel segments and 
additional stenting should be made. 
No re-treatment Re-treatment p Value 
New stents (%) 12 42 <0.01 
Reference diam (mm) 2.84=0.45 2.86±0.40 0.8 
Lesion length (ram) 18.1 ±8.6 20.1 ±9.1 0.2 
Pre-MLD (mm) 0.60±0.44 0.58±0.42 0.8 
Final MLD (mm) 2.69±0.53 2.68±0.52 0.9 
In-hosp MACE (%) 0 2.1 0.3 
9-month MACE (%) 13.1 11.1 1.0 
g-month death (%) 2.1 0 1.0 
9-month MI (%) 2.1 8.9 0.08 
9-month TVR (%) 12.1 22.2 0.14 
9-month TLR (%) 10.1 6.7 0.8 
9-month TVR without TLR (%) 3.1 17.8 <0.01 
1196-22 Efficacy of Gamma Vascular Brachytherapy for Ostlal 
Versus Nonostlal In Stent Restenotlc Lesions 
Costantino O. Costantini. Alexandra J. Lansky, Roxana Mehran, Martin Fahy, Kazuyuki 
Shirai, Nishi Dave, Gragg W. Stone, George Dangas, Martin B. Leon, Cardiovascular 
Research Foundation, New York Cit~, New York. 
Background: In stent rostenosis (ISR) involving the coronary ostium is associated with 
high recurrence rates after conventional treatment compared to non-ostist lesions. 
Whether Gamma vascular brachytherapy (GVBT) significantly improves these outcomes 
is not known. Methods: Pts with native oetist coronary lesions (N=45) were selected from 
a pooled angiographic database of pts enrolled in Vascular Brechytherapy (VBT)trials for 
treatment of ISR and were compared to 232 pts with non-ostial lesions, matched for 
lesion length. Baseline and follow-up quantitative coronary angiographic (QCA) analysis 
were assessed and compared. Results: At baseline pts with ostial lesions had more com- 
plax lesions (ACC/AHA • BI: 73.3% vs. 53.8%, p<0.05), with more total occlusions 
(8.9% vs. 3.0%, p=0.08) compared to non-ostial pts. QCA results are presented in the 
table. 
Patients with VBT failure had a significant reduction in lesion length regardless the lesion 
location: ostist (14.2±9.49 to 6.94±3.69,p<0.05) and non-ostial (16.66±6.71 to 8.61±6.52, 
p<0.005).There were no difference in stent edge restenosis (6.7% vs. 9.1%,p=0.77) Con- 
clusions: Gamma radiation is at least as effective for treatment of ostial in-stent rest- 
enotic lesions as non-ostial lesions, decreasing rastenosis by 54% compared to non- 
ostial lesions. The difference was not related to edge restenosis. 
QCA analysis Ostial Non-Ostist p Value 
Lesion length Pre(mm) 14.2±9.4 16.6±6.7 0.25 
Lesion length FU(mm) 6.9¢3.6 8.6¢6.5 0.07 
Reference (mm) 2.71 ¢0.39 2.61 ±0.46 0,15 
Final DS% 26.9±14,5 27.8¢12.2 0,67 
FU DS% 36.8±21.7 47.2±25.1 0.009 
Late Loss (mm) 0.31±0.58 0.52±0.70 0.05 
Restenosis (%) 17.8 32.8 0.04 
1196-23 Repeat Intracoronary Radiation for  In-Stent Restenoala 
in Patients Who Failed Radiation Therapy: Re-WRIST 
Ron Waksman, Andrew E. Ajani, Edouard Cheneau, Rosanna C. Chan, Bill G. Bass, 
Katayoun Khosravani, Augusto D. Pichard, Lowell F. Satler, Kenneth M. Kent, Ellen 
Pinnow, Joseph Lindsay, Washington Hospital Center, Washington, Dist. of Columbia. 
Background: Intracoronary Radiation (IR) is proven as an effective therapy to prevent 
recurrences of in-stent restenosis (ISR). However nearly 20% of the patients (pts) 
enrolled in radiation studies for ISR required repeat revasculadzation to the irradiated 
site. Re-WRIST (Washington Radiation for In-Stent Restenosis Trial) is a registry evalu- 
ating the safety and efficacy of re-treatment with IR in pts with refractory ISR. 
Methods: Patients with ISR who had recurrence of stenosis at a previously irradiated 
segment and failed a subsequent additional angioplasty were eligible for re-treatment 
with IR, if evaluated as a poor surgical candidate. In Re-WRIST, the radiation system is a 
0.0030-inch nylon ribbon containing 1921r seeds manufactured by Best Industries deliv- 
ered into a non.centered end lumen delivery catheter (Cordis 4F or Mecitronic 5F). The 
prescribed dose is 15 Gy to a 2 mm radial distance from the center of the source. All pts 
receive 6 months of clopidogrel post-procedure. Patients are followed clinically, anglo- 
graphically and by IVUS at 6 and 24 months. 
Results: At present, 9 pts have been enrolled in the Re-WRIST registry, The mean age 
of the cohort is 65 ± lOyrs (4 males, 3 diabetics and 7 pts had previous CABG). Five ISR 
lesions were in native coronary artedes, 3 in saphenous vein grafts and one in left inter- 
nal mammary artery. The mean time interval between radiation treatments is 18 months 
(range 6.4-28.9) and the mean number of previous interventions to the target lesion is 
4.1 ± 1.5. The radiation was delivered successfully in all pts with no procedural or hospi- 
tal complications. Balloon sngiopleety alone wee performed in 6 of 9 pts, 2 pts were 
treated with the excimer laser and 1 pt with the cutting balloon. None of the pts received 
additional stants. At 30 days, there were no reported clinical events. 
Conclusions: Repeat radiation to the same site using 192-1r for refractory ISR is safe 
and effective at 30 days. Complete 6-month clinical and anglographic follow-up will be 
available at presentation. 
1196-24 Age Is an Important Prsdictor of Clinical Outcomes 
Following Intracoronary Radiation Therapy for In-stent 
Restenoals 
Andrew E. Aiani. Edouard Cheoeau, R. Larry White, Bill G. Bass, Augusto D. Pichard, 
Lowell F. Satier, Kenneth M. Kent, Melanie Odnger, Chades Duncan, Ellen Pinnow, 
Joseph Lindsay, Ron Waksman, Washington Hospital Center, Washington, Dist. of 
Columbia. 
Background: Intracoranary radiation therapy (IRT) reduces the recurrence rate of in- 
stent restenosis (ISR) by inhibition of smooth muscle cell proliferation. The ability of 
these calls to replicate is limited with age due to changes in the tstomeres. The purpose 
of this study was to assess the effect of age on clinical outcomes following IRT for ISR. 
Methods: We evaluated 1275 patients (pts) with 6-month (mo) clinical follow-up who 
were enrolled in radiation tdals for ISR using gamma and beta emitters conducted at the 
Washington Hospital Center. Patients with ISR who were assigned to IRT (N=1025) or 
placebo (N=250) were analyzed In 4 age groups: (<55 yrs, 55-64 yrs, 65-75 yrs, >75 yrs). 
Results: Baseline clinical and angiographic haracteristics were similar within each age 
group of IRT pts, except for a higher rate of diabetes in younger pts (42% in pts <75 yrs 
vs. 30% in pts >75 yrs, p=0.002) and a higher rate of previous CABG in older pts (58% in 
pts >75 yrs vs. 37% in pts <55 yre, p< 0.001). The clinical outcomes at 6 mos for IRT 
treated pts are shown (Table). No effect of age was seen in placebo pts. IRT treated pts 
had reduced MACE compared to placebo in all age groups, driven by reduced target ves- 
sel revasculadzation (TVR). Multivariate analysis detected age as an independent pre- 
dictor of MACE at 6 mths (odds ratio 0.8, CI. 0.70-0.93, p=0.O04). Conclusions: Elderly 
pts (>75 yrs) potentially dedve the maximum benefit from IRT for ISR as recurrent rest- 
enosis is significantly reduced compared to younger pts. 
< 55 yrs 55-64 yrs 65-75 yrs >75 yrs P 
(N=268) (N=.321) (N=314) (N=122) 
Death, % 1 3 4 4 NS 
Q-Wave-MI, % 2 1 1 1 NS 
TLR, % 19 21 13 8 0.002 
TVR, % 28 26 19 16 0.005 
MACE, % 28 28 20 18 0.02 
Late Thrombosis, % 3 2 1 1 NS 
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1197-6 Neuroprotect ion Reduces the Risk of PerI-Procedursl 
Major Strokes and Death in Octogenarians 
Christina Brennan, Gary S. Roubin, Sdram S. lyer, Sara Mgaieth, Paliavi Kumar, Nedim 
AI-Mubarak, Roxana Mehran, George Dangee, Martin B. Leon, Jid J. Vifek, Gishst New, 
Lenox Hill Heart and Vascular Institute, NY, New York, Cardiovascular Research 
Foundation, NY, New York. 
Background: Our previous work in carotid stenting (CS) suggested that patients > 80 
years of age compared with those < 80 are higher- risk for procedural related stroke. 
Since then, we have altered our strategy of performing CS in • 80 years under neuropro- 
tection (NP). The aim of this study was to compare procedural outcomes in patients -> 80 
years with and without distal embolic protection. 
Methods: Thirty- day outcomes (TIA, minor strokes, major strokes and myocardial inf- 
arction) were prospectively examined in those patients > 80 years of age who had under- 
gone CS with and without NP. 
Results: There were no differences in age, % female, presence of risk factors, CAD, 
contraleterel occlusion, and procedural success between the two groups. There were 
more patients in the NP group who were asymptomatic (64% vs. 44%), and with prior 
carotid endartarectomy (23% vs. 10%). 
30 Day Outcomes Without NP With NP 
Patient 91 47 
Minor Stroke 7 (7.7%) 3 (6.4%) 
Major Stroke 6 (6.6%) 0 
Fatal Stroke t (1.1%) 0 
Non- Stroke Death 1 (1.1%) 1 (2.1%) 
Total 15 (16%) 4 (8.5%) 
*P= 0.06 
